SCHEMBL27009249

SCHEMBL27009249

CC(C)(C)c1ccn(-c2cccc(Br)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGLL Q99685 1/20 0.38
HTT P42858 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ATM Q13315 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
GPR35 Q9HC97 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
DHFR P00374 1/20 0.35
RXRA P19793 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17633620 0.84 NPC1 (0.45) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL26251823 0.82 MEN1 (0.51) ALDH1A1MEN1KMT2AMGLLHTT
SCHEMBL1600266 0.81 NOTUM (0.49) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL18997032 0.81 KEAP1 (0.49) MGLLRXRAGRIN1GRIN2B
SCHEMBL27013408 0.79 NOTUM (0.53) ALDH1A1MAPTMGLLHTTLMNA
SCHEMBL7839870 0.79 ELOVL1 (0.45) MAPTMEN1KMT2AHTTKDM4E
SCHEMBL5535694 0.78 MAPT (0.50) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL30474527 0.78 MAPT (0.50) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL30264109 0.75 SMN1; SMN2 (0.41) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL15352749 0.75 SMN1; SMN2 (0.41) ALDH1A1MAPTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 ALDH1A1 4878/4885MAPT 682/4885MEN1 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.